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Identifying candidate disease genes is important to improve medical care. However, this task is challeng-
ing in the post-genomic era. Several computational approaches have been proposed to prioritize potential
candidate genes relying on protein–protein interaction (PPI) networks. However, the experimental PPI
network is usually liable to contain a number of spurious interactions. In this paper, we construct a reli-
able heterogeneous network by fusing multiple networks, a PPI network reconstructed by topological
similarity, a phenotype similarity network and known associations between diseases and genes. We then
devise a random walk-based algorithm on the reliable heterogeneous network called RWRHN to
prioritize potential candidate genes for inherited diseases. The results of leave-one-out cross-validation
experiments show that the RWRHN algorithm has better performance than the RWRH and CIPHER
methods in inferring disease genes. Furthermore, RWRHN is used to predict novel causal genes for 16
diseases, including breast cancer, diabetes mellitus type 2, and prostate cancer, as well as to detect
disease-related protein complexes. The top predictions are supported by literature evidence.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Elucidating the underlying molecular mechanisms basis of dis-
eases has become increasingly important in disease prevention,
diagnosis, and drug design. Understanding the relationship
between causal genes and their associated genetic diseases is an
important topic in systems biology. Candidate gene prioritization
is the process of identifying new genes as potential candidates of
being associated with a phenotype or a disease. This process is
an important issue in current biomedical research.
Many approaches have been developed to identify candidate
genes [1]. A common approach is the analysis of inherent sequence
characteristics and similarities between candidate genes and
known disease causal genes based on characteristics such as
protein sequence properties [2], gene expression data [3],
functional annotations [4], and relevant biomedical literature [5].
However, these approaches suffer from inherent limitations.
That is, these methods rely on the quality and completeness of
biological information.
Network-based approaches have been recently developed and
applied to candidate gene prioritization [6–9]. Studies on theproperties of disease genes in molecular networks have shown that
two genes sharing higher-order topological similarities are likely to
interact with each other and may be associated with the same or
similar phenotypes [10–12]. In addition, disease phenotypic data
can help increase the gene prediction accuracy for less-studied
disease phenotypes. These ﬁndings have become the basis for the
development of computational approaches to predict and prioritize
potential candidate genes for inherited diseases. Dezso et al. [6]
applied an adapted version of shortest path betweenness to
prioritize candidate genes in PPI networks. A candidate gene was
scored more relevant to the disease of interest if it laid more on
signiﬁcantly shorter paths connecting nodes of known disease
genes than other genes in the network. Wu et al. [7] established
a regression model that measures the correlation between gene
closeness and phenotype similarities in the PPI network to
prioritize potential candidate genes for inherited diseases on the
basis of correlation scores. Li and Patra [8] proposed a new method
to prioritize disease genes by extending the random walk with
restart algorithm on a heterogeneous network constructed by
connecting the gene network and the phenotype similarity
network using known gene-phenotype relationships. Yang et al.
[9] recently exploited known gene–phenotype associations to
represent higher-level complex phenotype associations on the
basis of the modular nature of complex diseases. They then prior-
itized potential candidate disease genes for disease phenotypes
Fig. 1. The overall framework of the RWRHN algorithm.
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Of these network approaches, the random walk with restart
algorithm is a state-of-the-art approach. Tong et al. [13] proposed
fast solutions to the problem in which random walk with restart
did not scale for large graphs. Zhu et al. [14] proposed a method
to prioritize potential candidate disease genes based on the linear
correlation coefﬁcient and cosine angle of corresponding diffusion
proﬁles. The diffusion proﬁle of a disease was deﬁned as the sta-
tionary distribution of all genes under a random walk with restart
on the phenotype similarity network. The diffusion proﬁle of a
gene was obtained by smoothing the probability distribution over
the PPI network when starting a walk from this gene.
However, the experimental PPI network usually contains spuri-
ous interactions. Therefore, combining the topological similarities
of the PPI network with gene–phenotype relationship information
is essential to accurately predict disease genes. PPI network recon-
struction is proposed to improve the prediction accuracy of disease
genes further. Gene–gene interactions are measured according to
topological similarity, after which the phenotype similarity
network is connected with the use of known gene–phenotype
relationships to construct a reliable heterogeneous network. The
novel algorithm RWRHN (Random Walker on the Reliable Hetero-
geneous Network) is proposed to predict and prioritize potential
candidate genes for inherited diseases on such a heterogeneous
network. Comparisons of RWRHN with CIPHER [7] and RWRH [8]
show that the novel algorithm has better performance.
Furthermore, RWRHN is used to predict novel causal genes for 16
diseases, including breast cancer, diabetes mellitus type 2, and
prostate cancer, and to detect disease-related protein complexes.
The top predictions are supported by literature evidence.2. Materials and methods
2.1. Data sources
The protein–protein interaction (PPI) data were downloaded
from the Human Protein Reference Database (HPRD) [15]. The
phenotype similarity network which was a k nearest neighbor
(KNN) graph presentation of the phenotypic similarity matrix con-
structed by van Driel et al. [16] was downloaded from MimMiner
[17]. Gene–phenotype relationships were obtained from the OMIM
database [18] and extracted using BioMart [19]. The data sources
are available in the Supplementary Material.2.2. RWRHN algorithm
Two genes that share higher-order topological similarities are
likely to interact with each other and may be associated with the
same or similar phenotypes [10–12]. The RWRHN method is
predicated on the basis of this simple observation together along
with a novel link prediction algorithm [20]. The topological proﬁle
is calculated for each gene to measure the ‘‘distances’’ between the
target gene and all other genes in the network. Then, the similari-
ties of topological proﬁles are calculated between each gene pair.
Finally, interactions are created to connect topologically similar
genes. The PPI network is reconstructed from the topological sim-
ilarity matrix by connecting pairs of genes whose similarities are
above a certain threshold. Then, a reliable heterogeneous network
is constructed by fusing a PPI network reconstructed by topological
similarity with a phenotype similarity network and known associ-
ations between diseases and genes. Finally, the random walk with
restart on the heterogeneous network model [8] is used to
prioritize candidate genes. Fig. 1 shows the overall framework of
the RWRHN algorithm.2.3. Constructing reliable heterogeneous network
The experimental PPI network usually contains spurious inter-
actions. Thus, a novel link prediction algorithm [20] consisting of
the random walk with resistance algorithm (RWS) and using the
Pearson correlation coefﬁcient to compute similarity is used to
reconstruct the network. This algorithm combines the simple com-
mon neighbor-based method with ideas from the distance-based
method. The PPI network is reconstructed from the topological
similarity matrix by connecting pairs of genes whose similarities
are above a certain threshold. Compared with the original data,
the reconstructed data contain some new edges with high
topological similarities and lack edges with low topological
similarities. Lei et al. have reported that the new protein–protein
interactions have high functional relevance and are likely bona ﬁde
physical interactions [20]. The PPI network can be regarded as an
undirected graph G(V, E), where V is the set of genes and E is the
set of interactions. For v e V, N(v) = {u e V|(v, u) e E} is the set of
neighbors of v and d(v) = |N(v)| is the degree of v.
RWS is used to compute the topological proﬁles for each gene.
With the basic random walk idea, the probability of an initial gene
i to move to its neighbor gene j in the next step is Pij = 1/d(i) for
(i, j) e E. When the random walker initiates at a gene v, then the
probability of the randomwalker sitting at gene i at a discrete time
point k is qðkÞv ;i . The stationary probability distribution obtained from
the simple random walk cannot be directly used to measure the
distance between nodes [21]. Thus, RWS uses two resistances, e
and b. The former is used to differentiate the ﬁnal convergence
status from each gene based on its topology within the PPI net-
work. The latter is used to control the depth of a random walk
and avoid the hub gene effect. The probability of a random walker
initiating from gene v to take the interaction (i, j) at time point k + 1
can be calculated by Eq. (1).f ðkþ1Þv;ij
maxð0; qðkÞv;i Pij  eÞ; if qðkÞv;j > 0;
maxð0; qðkÞv;i Pij  eÞ; if qðkÞv;j ¼ 0 maxt ðq
ðkÞ
v;tPijÞP b;
0; otherwise:
8><
>>:
ð1Þ
At time point k + 1, the probability of the random walker to
reach gene j can be calculated asqðkþ1Þv;j ¼
X
i
f ðkþ1Þv;ij ð2Þ
In our method, e and b are set to |V|/|E|2 and 1/|E|, respectively.
The topological proﬁles are obtained for each gene when the RWS
algorithm is applied to the original PPI network.
The Pearson correlation coefﬁcients of the topological proﬁles
between all pairs of genes are calculated to represent the topolog-
ical similarity between two genes. The pairs of genes with similar-
ities that are above a certain threshold are connected to retain the
same number of interactions as in the original network in our
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similarity matrix.
A reliable heterogeneous network is then constructed. This net-
work is composed of a PPI network U(nn) reconstructed by topo-
logical similarity, a phenotype similarity network V(mm), and
known associations between diseases and genes. The gene–
phenotype relationship is represented as a bipartite graph G(nm).
Therefore, the adjacency matrix of our reliable heterogeneous
network can be represented as A ¼ U GGT V
 
, where GT represents
the transpose of G.
2.4. Prioritization of candidate disease genes
The random walk with restart (RWR) [22] algorithm is a com-
mon approach to prioritize candidate genes. This algorithmmimics
a walker that moves from a seed gene to a randomly selected
neighbor gene or returns to seed genes with a probability c. All
genes in the network are ranked by the probability of the random
walker reaching this gene. Formally, the random walk with restart
can be given by:
psþ1 ¼ ð1 cÞMTps þ cp0 ð3Þ
where c e (0,1) is the restart probability, p0 is the initial probability
vector, and ps is a vector in which the i-th element holds the
probability of ﬁnding the random walker at gene i at step s. M is
the transition matrix of the network, and Mij is the transition
probability from gene i to gene j. The probability will reach a steady
state after some steps. This state is obtained by performing
iterations until the change between ps and ps+1 (measured by the
L1 norm) falls below 1010. If p1(i) > p1(j), then gene i is more prox-
imate to seed genes than gene j.
In RWRHN, the random walk with restart on the reliable
heterogeneous network model [8] that utilizes a phenotype
similarity network with a PPI network is used to prioritize candi-
date genes. The transition matrix of the reliable heterogeneous
network is represented as M ¼ MU MUV
MVU MV
 
. The parameter k is
the jumping probability that the random walker shifts from the
PPI network to the phenotype similarity network, or vice versa.
The known associations between diseases and genes are repre-
sented as a matrix G = (gij)(nm), where gij = 1 indicates that the j-
th gene is associated with the i-th phenotype, and gij = 0 otherwise.
The transition probability from ui to vj or from vi to uj can be
described as
ðMuvÞi;j ¼
kgij
.X
j
gij; if
X
j
gij – 0
0; otherwise
8><
>: ð4Þ
ðMvuÞi;j ¼
kgji
.X
j
gji; if
X
j
gji – 0
0; otherwise
8><
>: ð5Þ
The reconstructed PPI network is represented as a matrix
U = (uij)(nn), where n denotes the number of genes. The element
of Mu is the probability of the random walker to transit from ui
to uj. This element can be described as
ðMuÞi;j ¼
uij
.X
j
uij; if
X
j
gij ¼ 0
ð1 kÞuij
.X
j
uij; otherwise:
8>><
>>:
ð6ÞThe phenotype similarity network is represented as a weight
matrix V = (vij) (mm), where m denotes the number of phenotypes
and vij is the similarity score between the i-th phenotype and the
j-th phenotype. The element ofMv is the probability of the random
walker to transit from vi to vj. This element can be described as
ðMvÞi;j ¼
v ij
.X
j
v ij; if
X
j
gji ¼ 0
ð1 kÞv ij
.X
j
v ij; otherwise:
8>><
>>:
ð7Þ
The parameters u0 and v0 represent the initial probability of the
reconstructed PPI network and phenotype similarity network,
respectively. With the sum of the probabilities equal to 1, the
vector u0 is constructed such that equal probabilities are assigned
to all the seed genes in the network. Similarly, the vector v0 is
given. The parameter g e (0,1) represents the probability that the
walker will select the query phenotype of interest as the starting
point. The initial probability vector of the reliable heterogeneous
network is represented as p0 ¼ ð1 gÞu0gv0
 
. The transition matrix
M and the initial probability p0 are substituted into the equation
Eq. (3). After some steps, the probability will reach a steady state
p1 ¼ ð1 gÞu1gv1
 
. Then genes are ranked based on the steady
probability.3. Results
3.1. Experimental settings and evaluation criteria
Leave-one-out cross-validation is used to compare the proposed
algorithm with different algorithms. In each round of cross-
validation, one gene–phenotype association is removed. The
phenotype and the rest of the genes associated with this
phenotype are used as seed nodes. Except for seed nodes, the genes
in the PPI network are used as candidate genes. The proposed
algorithm is then executed to rank the genes. A disease gene
ranked as top 1 is considered a successful prediction. The number
of overall successful predictions is used to evaluate the perfor-
mance of different algorithms. Depending on the genes involved
in the ranking, the cross-validation experiment can be categorized
into two classes, whole genome evaluation and ab initio evaluation
[9]. Whole genome evaluation considers all genes that are unasso-
ciated with the query phenotype and then checks how many
known disease genes are still ranked as top 1 in the cross-
validation. Ab initio evaluation identiﬁes disease genes without
any known disease genes for those query phenotypes. For each
phenotype entity, all of its gene–phenotype associations are
removed. A prediction is considered successful if one of the known
causal genes related to the phenotype is ranked as top 1.
Two measures are also used to evaluate the performance of the
algorithm. Assuming N validations, we collect the same number of
ranking lists and calculate the number of disease genes ranking
ﬁrst in their corresponding list. Then, we divide this number by
N to obtain the fraction of disease genes ranking ﬁrst and call this
fraction precision (PRE). Finally, we calculate the area under the
curve (AUC) value below the area of the fraction of disease genes
ranking above a particular threshold and the fraction of control
genes ranking below this threshold.
3.2. Experimental results
In this section, we compare RWRHN with CIPHER [7] and RWRH
[8]. Then, we evaluate the performance of RWRHN and test the
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predict novel causal genes for 16 diseases, including breast cancer,
diabetes mellitus type 2, and prostate cancer, and to detect
disease-related protein complexes.
3.2.1. Comparison with CIPHER and RWRH
The experimental data that we use are the same as the RWRH
algorithm. The PPI network contains 34,364 interactions among
8919 genes. The phenotype similarity network includes phenotype
similarities for 5080 diseases. In total, 1428 gene–phenotype
associations are found between 937 genes and 1216 phenotype
entities.
The same number of edges is retained to reconstruct the PPI
network in RWRHN. This process adds some new edges with high
topological similarities to the PPI network and removes some
edges with low topological similarities from the network. The
group of edges present in the original PPI network is called the
‘‘before group’’, and that in the reconstructed PPI network is called
the ‘‘after group’’. Thus, new edges are in the ‘‘after group’’ but not
in the before one, and removed edges are in the ‘‘before group’’ but
not in the after one. Another version of RWRHN called RWRHN-RE
is proposed to further highlight the importance of constructing a
reliable heterogeneous network combined with the topological
similarity. RWRHN-RE adds the removed edges to the ‘‘after group’’
to reconstruct a new PPI network.
We compare the performance of RWRHN with those of CIPHER
and RWRH using whole genome evaluation and ab initio
evaluation (c = 0.7, k = g = 0.5). CIPHER-DN and CIPHER-SP are
two versions of CIPHER. Two deﬁnitions of topological distance
are explored on the basis of two different neighborhood systems:
shortest path (SP) and direct neighbor (DN). The overall compari-
son results of the different algorithms are shown in Table 1. In
whole genome evaluation, RWRHN-RE and RWRHN successfully
rank 255 disease genes and 247 disease genes as top 1,
respectively. By contrast, RWRH, CIPHER-DN, and CIPHER-SP only
rank 245, 165, and 153 disease genes at the top, respectively. In
ab initio evaluation, RWRHN-RE and RWRHN can predict 204 and
207 disease genes, respectively. Meanwhile, RWRH, CIPHER-DN
and CIPHER-SP successfully predict 201, 157, and 140 genes,
respectively.
3.2.2. Performance of algorithm
To further highlight the importance of the reliable heteroge-
neous network, the proposed evaluation criteria in RWRHN and
RWRH are calculated (c = 0.7, k = 0.8, g = 0.5). These results show
that RWRHN-RE, RWRHN, and RWRH achieve the average fraction
precision (PRE) rates of 22.05%, 20.67%, and 19.83%, respectively.
RWRHN-RE and RWRHN obtain average AUC values of 91.54%
and 85.63%, respectively. Although the AUC value is not consider-
ably improved, the fraction precision of potential candidate genes
for inherited diseases is improved by the RWRHN algorithm. The
PRE and AUC value curves are shown in Fig. 2.
3.2.3. Effects of parameters
RWRHN has three parameters, namely, c, k, and g. The parame-
ter c is the restart probability. This parameter only slightly affects
the results [20]. In this work, c is ﬁxed at 0.7.Table 1
Compare RWRHN with the CIPHER and RWRH algorithms.
Algorithm Whole genome evaluation Ab initio evaluation
RWRHN-RE 255 204
RWRHN 247 207
RWRH 245 201
CIPHER-DN 165 157
CIPHER-SP 153 140The parameter g controls the impact of seed phenotypes and
seed genes. We investigate how this parameter affects the perfor-
mance of the algorithm. RWRHN is executed with g values ranging
from 0.1 to 0.9 in steps of 0.1, whereas k is ﬁxed as 0.5 by using
leave-one-out cross-validation. As shown in Fig. 3, the
performance of the algorithm is measured through whole genome
evaluation and ab initio evaluation. The algorithm performs
slightly better when g is above 0.5. This result shows that
phenotype data functions in prioritizing potential candidate genes
for inherited diseases.
The parameter k is the jumping probability. This parameter
controls the reinforcement between the PPI network and the
phenotype network. To investigate the effect of this parameter,
RWRHN is also executed with k values ranging from 0.1 to 0.9 in
steps of 0.1, whereas g is ﬁxed as 0.5 by using leave-one-out
cross-validation. As shown in Fig. 3, the performance of the
algorithm is measured by using whole genome evaluation and ab
initio evaluation. The number of successful predictions for both
whole genome evaluation and ab initio evaluation increases with
increasing k. Therefore, the optimal values of k are suggested to
be within the wide range of 0.5–0.9. The performance of RWRH
is comparatively poor when k < 0.5. In addition, RWRHN is
considerably better than RWRH when k < 0.5 (Fig. 3). These results
suggest that RWRHN has better stability and accuracy in
prioritizing potential candidate genes for inherited diseases.
3.2.4. Inferring novel causal genes for breast cancer, diabetes and
prostate cancer
After validating the algorithm, RWRHN is executed to predict
new causing genes for 16 diseases (c = 0.7, k = 0.8, g = 0.5). The
results are shown in Table 2. The target disease phenotype is used
as the seed node. The resulting candidate genes are ranked over the
whole genome. The top 10 predictions for each disease are shown
in Table 2. The top 20 ranked genes associated with breast cancer
(MIM: 114480), diabetes mellitus type 2 (MIM: 125853), and pros-
tate cancer (MIM: 176807) are selected as case studies.
Breast cancer originates from breast tissue, particularly from
the inner lining of milk ducts or the lobules that supply milk to
the ducts. Table 3 shows the prediction results for breast cancer
(MIM: 114480). Of the top 10 predicted disease genes, nine genes
(BRCA1, PIK3CA, NBN, BRCA2, RAD51, BRIP1, TP53, MSH2, and RB1)
associate with breast cancer. The correctness is as high as 90%.
However, we investigate whether or not the predicted novel sus-
ceptible genes are associated with disease. The novel susceptible
genes, which are predicted to be associated with breast cancer
by RWRHN, are supported by literature and the GENECARDS data-
base [23]. For MDC1, the tenth ranked gene is expressed as a prog-
nostic marker for nodal recurrence in early-stage breast cancer
patients [24]. Bonache et al. [25] reported that SHFM1 is bound
in mammalian cells to the region of the BRCA2 gene and associated
with breast cancer. C11orf30 (EMSY gene) links the BRCA2 path-
way to sporadic breast and ovarian cancer [26]. Finally, RNASEL
[27] and PTEN [28] genes are found to be related to breast cancer.
Diabetes mellitus is a metabolic disease characterized by a high
blood sugar. Table 3 shows our prediction results for diabetes mel-
litus type 2 (MIM: 125853). Of the top 10 predicted disease genes,
six genes (IPF1, NEUROD1, IRS1, MAPK8IP1, SLC2A4, and IRS2)
associate with the phenotype. MAFA, implicated in animal models
of type 2 diabetes, is markedly decreased in humans with type 2
diabetes [29]. MAPK8IP2, the IB2 gene, is a novel candidate gene
for diabetes [30]. SOCS2, which is ubiquitously expressed in human
tissues, has been found to contribute to susceptibility to type 2 dia-
betes in a Japanese population [31]. Finally, INSR [32] and PPP1R3A
[33] genes are found to be related to diabetes mellitus.
Prostate cancer develops in the prostate, a gland in the male
reproductive system. Table 3 shows our prediction results for
Fig. 2. Performance of algorithm. (A) Precision. (B) AUC value.
Fig. 3. Effect of value g, k based on whole genome and ab initio evaluation.
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Table 2
Top 10 predicted causal genes for 16 diseases predicted by RWRHN.
Phenotype MIM Top-10 predictions for each phenotype by RWRHN algorithm
Breast cancer 114,480 BRCA1 PIK3CA NBN BRCA2 RAD51 BRIP1 TP53 MSH2 RB1 MDC1
Diabetes mellitus 125,853 IPF1 NEUROD1 IRS1 TCF2 INSR MAPK8IP1 PPP1R3A SLC2A4 TCF1 IRS2
Prostate cancer 176,807 RNASEL PTEN ELAC2 MVP ABCE1 RNASE2 RET RING1 FHL1 CBX4
Alzheimer disease 104,300 PSEN2 APP MAPT HD PSEN1 CST3 HADH2 APBA3 SPON1 TM2D1
Colon cancer 114,500 ZCCHC10 AXIN2 CSNK1E ANKRD6 APC BRCA1 MSH2 MUTYH STK11 KIT
Gastric cancer 137,215 MUTYH SMAD4 TP53 RPA1 RPA3 RPA2 RPA4 AICDA UNG MSH6
Atrial ﬁbrillation 147,050 MUC7 SOCS3 FLG TGFBI CPN1 GFI1 CYBB ALG9 FIP1L1 PDGFRA
Schizophrenia 181,500 DISC1 RGS4 TRAF3IP1 APOE SNCA ADORA1 RGS5 RGS18 FFAR2 GPSM2
Leukemia/lymphoma 190,685 ZFHX1B CREBBP MECP2 UBE3A PSEN2 APP MSX1 TWIST1 MAPT PTEN
Lung cancer 211,980 TP53 EGFR BRAF SFTPA1 OIP5 MRAS KRAS RAF1 RALGDS RASIP1
Zellweger syndrome 214,100 PEX26 PXMP3 PEX6 PEX10 PEX12 PEX5 PEX19 PEX3 PEX1 PEX7
Leukemia 253,310 IGHMBP2 DTNA SMN1 SMN2 HSPB8 DCTN1 TNNT1 VAPB AR BIRC1
Asthma 600,807 MUC7 GGT1 GALNT12 GALNT14 MUC13 GALNT10 AMY1A MUC2 HTN3 PLEKHM1
Leukemia 601,626 RUNX1 IRF1 LYL1 MLL GFI1 CBFB MYST4 CACNA1A THPO ARL11
Obesity 601,665 POMC MC4R AGRP LEP PPARG NR0B2 UCP3 MC2R F11R MC5R
Tuberculosis 607,948 CFP C5 C8B CD8A TLR5 C3 C2 CFB GPR77 C4B
Table 3
Breast cancer, diabetes mellitus, type 2 and Prostate cancer genes prediction.
Breast cancer Diabetes mellitus, type 2 Prostate cancer
Rank Gene symbol aMark Rank Gene symbol Mark Rank Gene symbol Mark
1 BRCA1 ⁄ 1 IPF1 ⁄ 1 RNASEL
p
2 PIK3CA ⁄ 2 NEUROD1 ⁄ 2 PTEN ⁄
3 NBN ⁄ 3 IRS1 ⁄ 3 ELAC2
p
4 BRCA2 ⁄ 4 TCF2  4 MVP 
5 RAD51 ⁄ 5 INSR
p
5 ABCE1
p
6 BRIP1 ⁄ 6 MAPK8IP1 ⁄ 6 RNASE2 
7 TP53 ⁄ 7 PPP1R3A
p
7 RET
p
8 MSH2 ⁄ 8 SLC2A4 ⁄ 8 RING1
p
9 RB1 ⁄ 9 TCF1  9 FHL1 
10 MDC1
p
10 IRS2 ⁄ 10 CBX4
p
11 SHFM1
p
11 MAFA
p
11 CBX7
p
12 PCID2  12 DUSP16  12 BMI1 p
13 C11orf30
p
13 MAPK8IP2
p
13 CTBP2
p
14 DMC1  14 MAPK8IP3  14 PIK3CA 
15 RAD51AP1  15 RREB1  15 BRCA1 p
16 RAD54L ⁄ 16 SOCS2
p
16 NBN
p
17 RNASEL
p
17 ATP2A1  17 BRCA2 ⁄
18 PTEN
p
18 ATP2A2  18 RAD51 
19 ELAC2  19 PLN  19 BRIP1 p
20 ZNF278  20 SLN  20 PARP4 
a Genes marked with ⁄ are known disease genes associated with phenotype, genes marked with
p
are the genes associated with disease either extracted from literature or
from databases, genes marked with  are un-related to disease.
Table 4
Alzheimer’s disease, Leukemia and Zellweger syndrome top 20 genes prediction.
Alzheimer’s disease Leukemia Zellweger syndrome
Rank Gene symbol Rank Gene symbol Rank Gene symbol
1 PSEN2 1 RUNX1 1 PEX26
2 APP 2 IRF1 2 PXMP3
3 MAPT 3 LYL1 3 PEX6
4 HD 4 MLL 4 PEX10
5 PSEN1 5 GFI1 5 PEX12
6 CST3 6 CBFB 6 PEX5
7 HADH2 7 MYST4 7 PEX19
8 APBA3 8 CACNA1A 8 PEX3
9 SPON1 9 THPO 9 PEX1
234 J. Luo, S. Liang / Journal of Biomedical Informatics 53 (2015) 229–236prostate cancer (MIM: 176807). Two genes (PTEN and BRCA2)
associate with the phenotype. RET, the seventh ranked gene, is
involved in the growth of prostate epithelial cells and is overex-
pressed in prostate cancer [34]. RING1 is associated with adverse
pathologic features and clinical PSA recurrence of prostate cancer
[35]. CBX7, as a novel PcG protein controlling the growth of normal
cells, is highly expressed in three prostate cancer cell lines and is
upregulated in the normal prostate [36]. Finally, the RNASEL [37],
ELAC2 [38], ABCE1 [39], CBX4 [40], BMI1 [41], CTBP2 [42], BRCA1
[43], NBN [44], and BRIP1 [45] genes are reported to be related to
prostate cancer. These data show that our predictive method can
discover novel disease genes beyond the original disease gene set.10 TM2D1 10 ARL11 10 PEX7
11 TYROBP 11 ALAS2 11 ABCD1
12 TREM2 12 WRN 12 HSD17B4
13 METTL2B 13 TSC2 13 PLXNA2
14 DOCK3 14 TAL1 14 OCRL
15 NCSTN 15 DRG1 15 PEX14
16 APH1A 16 RWDD1 16 PEX16
17 APH1B 17 DRG2 17 PEX11A
18 PSENEN 18 GATA3 18 PEX11B
19 KCNIP3 19 LMO1 19 SLC25A17
20 ZFHX1B 20 TAL2 20 PXMP43.2.5. Detecting disease-related protein complexes
Genes sharing some higher-order topological similarities are
likely to interact with each other. Combining network-based dis-
ease studies, we conclude that genes associated with a particular
disease tend to exhibit high connectivity and cluster together
[10,46,47]. Many of the highly ranked genes predicted by RWRHN
have high-order topological similarities and are likely to cluster
together. In addition, these genes may originate from the same
J. Luo, S. Liang / Journal of Biomedical Informatics 53 (2015) 229–236 235disease-related protein complexes. Based on the gene ranking list
from Table 4, we investigate three protein complexes, namely,
gamma-secretase complex, RUNX1-CBF-beta-DNA complex, and
Pex26-Pex6-Pex1 complex, which were extracted from the CORUM
database [48]. These complexes are composed of top-ranked genes.
The gamma-secretase complex contains four genes: APH1A,
NCSTN, PSEN1, and PSENEN. These four genes are all ranked at
top 20 in predicting Alzheimer’s disease (MIM: 104300) by the
RWRHN algorithm. The four membrane genes comprise the
limiting components of gamma-secretase and co-assemble to form
the active enzyme in mammalian cells. These data suggest that the
gamma-secretase complex is crucial in the pathogenesis of
Alzheimer’s disease [49].
Similarly, the RUNX1-CBF-beta-DNA complex contains two
genes: RUNX1 and CBFB. These genes are respectively ranked at
top 1 and top 6 in inferring leukemia (MIM: 601626). The
RUNX1-CBF-beta-DNA complex is the most common target for
mutations in human leukemia [50]. Its structure reveals that the
Runt domain DNA binding mechanism is unique within the p53
family of transcription factors. This result indicates that the
RUNX1-CBF-beta-DNA complex is a consequence of human dis-
ease-associated mutations in leukemogenesis and cleidocranial
dysplasia.
The Pex26–Pex6–Pex1 complex contains three genes: Pex26,
Pex6, and Pex1. These genes are ranked at top 10 in inferring Zell-
weger syndrome (MIM: 214100). This result suggests that the
Pex26–Pex6–Pex1 complex is involved in peroxisome biogenesis
disorders (PBDs), which include the Zellweger syndrome spectrum
(PBD-ZSD) and rhizomelic chondrodysplasia punctata type 1 [51].
These data show that our predicted disease genes and disease-
related protein complexes indeed map signiﬁcantly with complex
genetic diseases that are extracted from literature or databases.
Combining the network topological similarity with disease pheno-
type data will facilitate the detection of disease-related protein
complexes and will contribute to the prevention, diagnosis and
treatment of diseases in the future.4. Conclusion
In this paper, we devise a random walk-based algorithm on the
reliable heterogeneous network called RWRHN to prioritize poten-
tial candidate genes for inherited diseases. The reliable heteroge-
neous network is composed of a PPI network reconstructed by
topological similarity, a phenotype similarity network and known
associations between diseases and genes. The results of leave-
one-out cross-validation experiments show that the performance
of RWRHN is better than those of CIPHER and RWRH. Another
advantage of the RWRHN algorithm is that it is still in good perfor-
mance when k < 0.5. Finally, RWRHN is used to predict new causal
genes for 16 diseases, including breast cancer, diabetes mellitus
type 2, and prostate cancer and to detect disease-related protein
complexes. The top predictions are supported by literature evi-
dence. These data suggest that constructing a reliable heteroge-
neous network is an effective basis for the prioritization of
potential candidate genes for inherited diseases and for the detec-
tion of disease-related protein complexes, which is important to
improve medical care in the future biomedical research.
The computational methods are highly dependent on the qual-
ity of the underlying protein interaction data. These data are often
associated with high false positive and false negative rates, which
may have a negative impact on the performance in inferring
disease genes. It can be integrated some other information with
topological similarity to further improve our method, such as
protein sequences, molecular function, motif protein localization,
biological process, gene expression proﬁles and so on. Further-more, in vitro and in vivo experiments should also be conducted
to validate the novel causal genes, which can assist the treatment
of inherited diseases in the future.
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